'We are still without peers in biosimilars'

Biocon clocked 10% revenue growth in the Covid-hit M9FY21. In an interview with FE's Srinath Srinivasan, Kiran Mazumdar Shaw, executive chairperson, highlights the reasons for her confidence in the biosimilar business. Edited excerpts:.

from Google Alert - Business https://ift.tt/30spifN
Biocon clocked 10% revenue growth in the Covid-hit M9FY21. In an interview with FE's Srinath Srinivasan, Kiran Mazumdar Shaw, executive chairperson, highlights the reasons for her confidence in the biosimilar business. Edited excerpts:. https://ift.tt/eA8V8J

Comments

Popular posts from this blog

Jobless Rate Drops

Electrolytic Fixed Power Capacitors Market Competitive intelligence & regional outlook 2020

USU project among finalists for $3 million solar energy tech prize